HCC and angiogenesis: possible targets and future directions (original) (raw)

• Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010).
  Article CAS PubMed Google Scholar
• Thomas, M. B. & Zhu, A. X. Hepatocellular carcinoma: the need for progress. J. Clin. Oncol/ 23, 2892–2899, (2005).
  Google Scholar
• Fong, Y., Kemeny, N. & Lawrence, T. S. in Cancer, Principles and Practice of Oncology 6th edn (eds DeVita, V. T., Hellman, S. & Rosenberg, S. A.) 1162–1203 (Lippincott Williams and Wilkins, Philadelphia, PA, USA, 2001).
  Google Scholar
• Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273–286 (2007).
  CAS PubMed Google Scholar
• Van de Veire, S. et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178–190 (2010).
  CAS PubMed Google Scholar
• Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
  CAS PubMed Google Scholar
• Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
  CAS PubMed Google Scholar
• Sun, H. C. & Tang, Z. Y. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J. Cancer Res. Clin. Oncol. 130, 307–319 (2004).
  PubMed Google Scholar
• Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
  CAS PubMed Google Scholar
• Jain, R. K. Taming vessels to treat cancer. Sci. Am. 298, 56–63 (2008).
  PubMed Google Scholar
• Naugler, W. E. & Karin, M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14, 109–119 (2008).
  CAS PubMed Google Scholar
• Zhu, A. X. et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 27, 3027–3035 (2009).
  CAS PubMed PubMed Central Google Scholar
• Abou-Alfa, G. K. et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293–4300 (2006).
  CAS PubMed Google Scholar
• Yang, Z. F. & Poon, R. T. Vascular changes in hepatocellular carcinoma. Anat. Rec. (Hoboken) 291, 721–734 (2008).
  CAS Google Scholar
• Fukumura, D., Yuan, F., Monsky, W. L., Chen, Y. & Jain, R. K. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am. J. Pathol. 151, 679–688 (1997).
  CAS PubMed PubMed Central Google Scholar
• Wu, X. Z., Xie, G. R. & Chen, D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 22, 1178–1182 (2007).
  CAS PubMed Google Scholar
• Jain, R. K., Tong, R. T. & Munn, L. L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67, 2729–2735 (2007).
  CAS PubMed PubMed Central Google Scholar
• LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890–893 (2003).
  CAS PubMed Google Scholar
• Lichtenberger, B. M. et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 140, 268–279 (2010).
  CAS PubMed Google Scholar
• Fukumura, D. et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61, 6020–6024 (2001).
  CAS PubMed Google Scholar
• Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).
  CAS PubMed Google Scholar
• Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368–4380 (2002).
  CAS PubMed Google Scholar
• Fukumura, D., Kashiwagi, S. & Jain, R. K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 6, 521–534 (2006).
  CAS PubMed Google Scholar
• Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715–725 (1998).
  CAS PubMed Google Scholar
• Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737–744 (2000).
  CAS PubMed PubMed Central Google Scholar
• Amarapurkar, A. D., Amarapurkar, D. N., Vibhav, S. & Patel, N. D. Angiogenesis in chronic liver disease. Ann. Hepatol. 6, 170–173 (2007).
  CAS PubMed Google Scholar
• Ho, J. W. et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44, 836–843 (2006).
  CAS PubMed Google Scholar
• Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685–693 (2003).
  CAS PubMed Google Scholar
• Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669–676 (2003).
  CAS PubMed Google Scholar
• Semela, D. & Dufour, J. F. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41, 864–880 (2004).
  PubMed Google Scholar
• Roberts, L. R. & Gores, G. J. Emerging drugs for hepatocellular carcinoma. Expert Opin. Emerg. Drugs 11, 469–487 (2006).
  CAS PubMed Google Scholar
• Mas, V. R., Maluf, D. G., Archer, K. J., Yanek, K. C. & Fisher, R. A. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation 84, 1262–1271 (2007).
  PubMed Google Scholar
• Poon, R. T. et al. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am. J. Surg. 182, 298–304 (2001).
  CAS PubMed Google Scholar
• Poon, R. T. et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann. Surg. 233, 227–235 (2001).
  CAS PubMed PubMed Central Google Scholar
• Dhar, D. K. et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res. 22, 379–386 (2002).
  CAS PubMed Google Scholar
• El-Assal, O. N. et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27, 1554–1562 (1998).
  CAS PubMed Google Scholar
• Park, Y. N., Kim, Y. B., Yang, K. M. & Park, C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch. Pathol. Lab. Med. 124, 1061–1065 (2000).
  CAS PubMed Google Scholar
• Yamaguchi, R. et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28, 68–77 (1998).
  CAS PubMed Google Scholar
• Li, X. M., Tang, Z. Y., Zhou, G., Lui, Y. K. & Ye, S. L. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 17, 13–17 (1998).
  PubMed Google Scholar
• Yao, D. F. et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 4, 220–226 (2005).
  CAS PubMed Google Scholar
• Zhou, J. et al. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J. Cancer Res. Clin. Oncol. 126, 57–61 (2000).
  CAS PubMed Google Scholar
• Poon, R. T. et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 91, 1354–1360 (2004).
  CAS PubMed Google Scholar
• Chao, Y. et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 10, 355–362 (2003).
  PubMed Google Scholar
• Tamesa, T. et al. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology 56, 1122–1126 (2009).
  CAS PubMed Google Scholar
• Xiong, H. Q. et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest. New Drugs 22, 459–466 (2004).
  CAS PubMed Google Scholar
• Li, X., Feng, G. S., Zheng, C. S., Zhuo, C. K. & Liu, X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 10, 2878–2882 (2004).
  CAS PubMed PubMed Central Google Scholar
• Shim, J. H. et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 99, 2037–2044 (2008).
  CAS PubMed Google Scholar
• Sergio, A. et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am. J. Gastroenterol. 103, 914–921 (2008).
  PubMed Google Scholar
• Poon, R. T. et al. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol. 14, 1835–1845 (2007).
  PubMed Google Scholar
• Cui, J., Dong, B. W., Liang, P., Yu, X. L. & Yu, D. J. Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J. Gastroenterol. 10, 1533–1536 (2004).
  CAS PubMed PubMed Central Google Scholar
• Hu, J. et al. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J. Cancer Res. Clin. Oncol. 135, 1359–1367 (2009).
  CAS PubMed Google Scholar
• Moon, J. I. et al. Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma [Korean]. Korean J. Hepatol. 14, 185–196 (2008).
  PubMed Google Scholar
• Jeng, K. S. et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J. Gastroenterol. 10, 643–648 (2004).
  CAS PubMed PubMed Central Google Scholar
• Jeng, K. S. et al. Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection? World J. Gastroenterol. 10, 676–681 (2004).
  CAS PubMed PubMed Central Google Scholar
• Ho, M. C. et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett. 250, 237–249 (2007).
  CAS PubMed Google Scholar
• Wada, H. et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 26, 414–423 (2006).
  CAS PubMed Google Scholar
• Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).
  CAS PubMed Google Scholar
• McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936–19941 (2007).
  CAS PubMed PubMed Central Google Scholar
• Dufour, J. F. et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 15, 1198–1204 (2010).
  CAS PubMed PubMed Central Google Scholar
• Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11–16 (2010).
  PubMed PubMed Central Google Scholar
• Van Cutsem, E., Lambrechts, D., Prenen, H., Jain, R. K. & Carmeliet, P. Lessons from the adjuvant bevacizumab trial in colon cancer: what next? J. Clin. Oncol. 29, 1–4 (2010).
  PubMed Google Scholar
• Arora, A. & Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971–979 (2005).
  CAS PubMed Google Scholar
• Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
  CAS PubMed Google Scholar
• Pawson, T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer 38 (Suppl. 5), S3–S10 (2002).
  PubMed Google Scholar
• Faivre, S. et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 10, 794–800 (2009).
  CAS PubMed Google Scholar
• Hoda, D. et al. Phase II study of sunitinib malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma (HCC) [abstract]. Proc. 2008 Gastrointestinal Cancers Symp. a267 (2008).
• Koeberle, D. et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 15, 285–292 (2010).
  CAS PubMed PubMed Central Google Scholar
• Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329–1338 (2006).
  CAS PubMed Google Scholar
• Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).
  CAS PubMed PubMed Central Google Scholar
• Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239 (2009).
  CAS PubMed PubMed Central Google Scholar
• Zhu, A. X. et al. A phase II study of ramucirumab as first-line monotherapy in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4083 (2010).
  Google Scholar
• Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 7, 987–989 (2001).
  CAS PubMed Google Scholar
• Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145–147 (2004).
  CAS PubMed PubMed Central Google Scholar
• Siegel, A. B. et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26, 2992–2998 (2008).
  CAS PubMed Google Scholar
• Zhu, A. X. et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 1898–1903 (2006).
  CAS PubMed Google Scholar
• Hsu, C. H. et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer 102, 981–986 (2010).
  CAS PubMed PubMed Central Google Scholar
• Sun, W. et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma: a phase II study [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a4574 (2007).
  Google Scholar
• Malka, D. et al. Bevacizumab in patients with advanced hepatocellular carcinoma: preliminary results of a phase II study with circulating endothelial cell monitoring [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a4570 (2007).
  Google Scholar
• Thomas, M. B. et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 27, 843–850 (2009).
  CAS PubMed Google Scholar
• Albert, D. H. et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 5, 995–1006 (2006).
  CAS PubMed Google Scholar
• Toh, H. et al. Linifanib phase II trial in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4038 (2010).
  Google Scholar
• Wedge, S. R. et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389–4400 (2005).
  CAS PubMed Google Scholar
• Alberts, S. R. et al. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma—interim review of toxicity [abstract]. Proc. 2007 Gastrointestinal Cancers Symp. a186 (2007).
• Yau, C. C. et al. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a3561 (2009).
  Google Scholar
• Wood, J. M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178–89 (2000).
  CAS PubMed Google Scholar
• Drevs, J. et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 62, 4015–4022 (2002).
  CAS PubMed Google Scholar
• Koch, I. et al. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics of PTK787/ZK 222584 in patients with unresectable hepatocellular carcinoma [abstract]. J. Clin. Oncol. 23 (16 Suppl.), a4134 (2005).
  Google Scholar
• Yau, T. et al. Phase 1–2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 116, 5022–5029 (2010).
  CAS PubMed Google Scholar
• Huynh, H. et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 14, 6146–6153 (2008).
  CAS PubMed Google Scholar
• Ohta, M. et al. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg. Today 39, 1046–1053 (2009).
  CAS PubMed Google Scholar
• Raoul, J. L. et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4577 (2009).
  Google Scholar
• Kanai, F. et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 67, 315–324 (2011).
  CAS PubMed Google Scholar
• Eder, J. P. et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 16, 3507–3516 (2010).
  CAS PubMed Google Scholar
• Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698–711 (2008).
  PubMed Google Scholar
• Zhu, A. X., Duda, D. G., Sahani, D. V. & Jain, R. K. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience and correlative studies. Cancer J. 15, 263–268 (2009).
  CAS PubMed PubMed Central Google Scholar
• Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205–216 (2000).
  CAS PubMed Google Scholar
• Faivre, S. J., Bouattour, M., Dreyer, C. & Raymond, E. Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J. Clin. Oncol. 27, e248–e250 (2009).
  CAS PubMed Google Scholar
• Bruix, J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421–430 (2001).
  CAS PubMed Google Scholar
• Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G. & Thrall, J. H. Imaging angiogenesis: applications and potential for drug development. J. Natl Cancer Inst. 97, 172–187 (2005).
  CAS PubMed Google Scholar
• Suzuki, C. et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28, 329–344 (2008).
  PubMed Google Scholar
• Forner, A. et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115, 616–623 (2009).
  PubMed Google Scholar
• Jain, R. K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327–338 (2009).
  CAS PubMed PubMed Central Google Scholar
• Farazi, P. A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674–687 (2006).
  CAS PubMed Google Scholar
• Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2, 826–835 (2002).
  CAS PubMed Google Scholar
• Zhu, A. X. et al. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value. Clin. Cancer Res. 17, 918–927 (2011).
  CAS PubMed Google Scholar
• Kumar, R. et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101, 1717–1723 (2009).
  CAS PubMed PubMed Central Google Scholar
• Toh, H., Chen, P. & Carr, B. et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4581 (2009).
  Google Scholar
• Shao, Y. Y. et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 116, 4590–4596 (2010).
  CAS PubMed Google Scholar
• DePrimo, S. E. et al. Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): analysis of correlations with outcome and tumor imaging parameters [abstact]. J. Clin. Oncol. 26 (Suppl.), a4593 (2008).
  Google Scholar
• Boige, V. et al. Circulating endothelial cells (CECs) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a4597 (2009).
  Google Scholar
• Kaseb, A. O. et al. Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4046 (2010).
  Google Scholar
• Shao, Y. et al. Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a4063 (2010).
  Google Scholar
• Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391–400 (2004).
  CAS PubMed Google Scholar
• Hood, J. D. et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404–2407 (2002).
  CAS PubMed Google Scholar
• Gagnon, M. L. et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc. Natl Acad. Sci. USA 97, 2573–2578 (2000).
  CAS PubMed PubMed Central Google Scholar
• Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005).
  CAS PubMed Google Scholar
• Gridley, T. Vascular biology: vessel guidance. Nature 445, 722–723 (2007).
  CAS PubMed Google Scholar
• Williams, C. K., Li, J. L., Murga, M., Harris, A. L. & Tosato, G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107, 931–939 (2006).
  CAS PubMed PubMed Central Google Scholar
• Leslie, J. D. et al. Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134, 839–844 (2007).
  CAS PubMed Google Scholar
• Ridgway, J. et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083–1087 (2006).
  CAS PubMed Google Scholar
• Hellstrom, M. et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776–780 (2007).
  PubMed Google Scholar
• Vincent, F. et al. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res. 69, 2853–2860 (2009).
  CAS PubMed Google Scholar
• Phung, T. L. et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10, 159–170 (2006).
  CAS PubMed PubMed Central Google Scholar
• Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
  CAS PubMed Google Scholar
• Pikarsky, E. et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461–466 (2004).
  CAS PubMed Google Scholar
• He, G. et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17, 286–297 (2010).
  CAS PubMed PubMed Central Google Scholar
• Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197–208 (2010).
  CAS PubMed PubMed Central Google Scholar
• Zhang, W. et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 16, 3420–3430 (2010).
  CAS PubMed Google Scholar
• Sakurai, T. et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14, 156–165 (2008).
  CAS PubMed PubMed Central Google Scholar
• Carmi, Y. et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J. Immunol. 183, 4705–4714 (2009).
  CAS PubMed Google Scholar
• Germano, G., Allavena, P. & Mantovani, A. Cytokines as a key component of cancer-related inflammation. Cytokine 43, 374–379 (2008).
  CAS PubMed Google Scholar
• Mizukami, Y. et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 11, 992–997 (2005).
  CAS PubMed Google Scholar
• Kubo, F. et al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann. Surg. Oncol. 12, 800–807 (2005).
  PubMed Google Scholar
• Brat, D. J., Bellail, A. C. & Van Meir, E. G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol. 7, 122–133 (2005).
  CAS PubMed PubMed Central Google Scholar
• Li, W., Gomez, E. & Zhang, Z. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 26, 527–533 (2007).
  CAS PubMed Google Scholar
• Grunewald, M. et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124, 175–189 (2006).
  CAS PubMed Google Scholar
• Mansuroglu, T. et al. Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma. Lab. Invest. 89, 562–574 (2009).
  CAS PubMed Google Scholar
• Wang, B., Gao, Z. Q. & Yan, X. Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol. 46, 353–358 (2005).
  CAS PubMed Google Scholar
• d'Assignies, G. et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 250, 407–416 (2009).
  PubMed Google Scholar
• Sahani, D. V., Holalkere, N. S., Mueller, P. R. & Zhu, A. X. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology 243, 736–743 (2007).
  PubMed Google Scholar
• Zhu, A. X., Holalkere, N. S., Muzikansky, A., Horgan, K. & Sahani, D. V. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 13, 120–125 (2008).
  CAS PubMed Google Scholar
• Liaw, J V. et al. Tumor vascularity assessment in hepatocellular carcinoma and disease free caudate and spleen before and after targeted therapy using a distributed parameter model [abstract]. Presented at RSNA 2009.
• Jarnagin, W. R. et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann. Oncol. 20, 1589–1595 (2009).
  CAS PubMed PubMed Central Google Scholar
• Sorensen, A. G. et al. A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296–5300 (2009).
  CAS PubMed PubMed Central Google Scholar
• Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).
  CAS PubMed PubMed Central Google Scholar
• Battistella, M. et al. Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J. Eur. Acad. Dermatol. Venereol. 24, 199–203 (2010).
  CAS PubMed Google Scholar
• Lassau, N. et al. Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Target. Oncol. 5, 53–58 (2010).
  PubMed Google Scholar